Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.43 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.43 |
| ▸ | PDXK | O00764 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridoxamine SCHEMBL30017752 | 0.86 | LMNA (0.79) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL30408 | 0.84 | LMNA (1.00) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL7749395 | 0.83 | LMNA (0.96) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL561421 | 0.83 | LMNA (0.96) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL48103 | 0.83 | LMNA (0.96) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxine SCHEMBL4576970 | 0.82 | KDM4E (0.77) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL3555546 | 0.81 | LMNA (0.93) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL9291549 | 0.81 | LMNA (0.93) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL4876978 | 0.81 | LMNA (0.93) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL9151731 | 0.81 | LMNA (0.69) | LMNAKDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3647430-B1 | MICROBIAL PRODUCTION OF FATTY AMINES | GENOMATICA INC (US) | 2022-10-26 | — | — | EP | disclosed |
| US-20150240226-A1 | NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM | BP CORP NORTH AMERICA INC (US) | 2015-08-27 | — | — | US | disclosed |
| US-8962800-B2 | Nucleic acids and proteins and methods for making and using them | BP CORPORATION NORTH AMERICA INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20120266329-A1 | Nucleic Acids and Proteins and Methods for Making and Using Them | BP CORPORATION NORTH AMERICA INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8119385-B2 | Nucleic acids and proteins and methods for making and using them | BP CORPORATION NORTH AMERICA INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110296543-A1 | NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM | THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-01 | — | — | US | disclosed |
| US-20100011456-A1 | Nucleic Acids and Proteins and Methods for Making and Using Them | VERENIUM CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| US-7635572-B2 | Methods for conducting assays for enzyme activity on protein microarrays | Life Technologies Corporation (US) | 2009-12-22 | — | — | US | disclosed |
| US-20050118665-A1 | Methods for conducting assays for enzyme activity on protein microarrays | PROTOMETRIX, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150240226-A1 | NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM | POLN, POLM, POLI | LMNA 389/4885KDM4E 3751/4885ALDH1A1 2292/4885 |
| US-20120266329-A1 | Nucleic Acids and Proteins and Methods for Making and Using Them | POLN, POLM, POLI | LMNA 389/4885KDM4E 3751/4885ALDH1A1 2292/4885 |
| US-20100011456-A1 | Nucleic Acids and Proteins and Methods for Making and Using Them | POLN, POLM, POLI | LMNA 389/4885KDM4E 3751/4885ALDH1A1 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.